What Verdica's 799 score means for HANDA THERAP
HANDA THERAP's composite score of 799 out of 850 places the provider in the "strong" band (740–799), indicating compliance performance that meets or exceeds baseline regulatory expectations across the dimensions Verdica tracks. A score in this range reflects a provider with a solid regulatory foundation: no major red flags in licensing, product approval, or federal compliance history, but also room for incremental improvement before reaching the "excellent" threshold (800–850).
For a business owner or procurement professional evaluating a pharmacy provider, a 799 score signals reliability relative to peers in elevated or acceptable bands. However, it is not a guarantee of service quality, pricing, or customer experience—those dimensions fall outside Verdica's compliance scope. The score specifically indicates that state boards of pharmacy, the FDA, and the DEA have not flagged material violations or licensing lapses that would warrant downward adjustment. A reader should interpret this as a baseline green light on regulatory standing, suitable for due diligence but not a substitute for direct reference checks, contracts, or service-level agreements with the provider.
How the sub-scores break down
Product Approval (850/850): This perfect sub-score indicates that HANDA THERAP's product portfolio—whether branded pharmaceuticals, generics, or compounded formulations—carries valid FDA approvals or exemptions as required. No entries appear in Verdica's data reflecting unapproved or misbranded products under the provider's name. In plain terms, what the pharmacy is selling meets federal authorization standards.
Manufacturer Profile (720/850): This mid-strong score suggests the provider's supply chain and manufacturing partnerships are broadly compliant but may carry minor deviations in quality assurance documentation, facility inspections, or supplier audits. A score of 720 is not a warning; it reflects that regulators have not identified systemic manufacturing defects or contamination events. However, it also suggests the provider may not be operating at the highest tier of GMP (Good Manufacturing Practice) certification or may have had routine inspection observations that do not rise to violation status.
FDA Compliance (830/850): A score of 830 reflects strong adherence to federal pharmacy regulations, including record-keeping, adverse event reporting, and product labeling requirements. The modest gap from a perfect score likely reflects minor documentation gaps, late filings, or routine compliance questions that were resolved, rather than substantive violations.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensing records, disciplinary histories, and operational compliance files for all registered entities. They monitor for lapses in continuing education, unauthorized practice, loss of facility licensure, or documented patient harm complaints that warrant board investigation.
The FDA tracks product approvals (NDA, ANDA, 505(b)(2) pathways), adverse event reports (MedWatch), and facility inspection findings. Pharmacies and their suppliers are subject to FDA inspections that assess manufacturing conditions, sterility protocols, and labeling accuracy. Inspection observations (Form 483s) and warning letters indicate areas of non-compliance; their absence or resolution reflects regulatory standing.
The DEA monitors controlled substance handling, record-keeping, and distribution through licensed pharmacy wholesalers. DEA compliance audits focus on inventory reconciliation, prescriber verification, and chain-of-custody documentation for Schedule II–V drugs.
Movement on these scores typically follows pattern changes: new violations, resolved warning letters, facility reinspections with passing marks, or changes in approved product portfolios all feed into Verdica's quarterly updates.
Bottom line
HANDA THERAP scores in the strong compliance band and carries no indexed red flags in product approval, FDA, or DEA records. For a baseline regulatory assessment, this provider merits consideration. Anyone entering a business relationship should still verify direct references, review the provider's most recent state board of pharmacy inspection report, and confirm product sourcing aligns with your organization's requirements.